Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
← catalyst calendarNCT06787612 · readout in 681 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
297estimated
Sites
55
Countries
Canada, South Korea, Taiwan +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-28 | actual | When the study began enrolling |
| Primary completion | 2028-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
Interventions
- Drug: Ubamatamab — also filed as REGN4018
- Drug: Bevacizumab — also filed as Avastin®
- Drug: Cemiplimab — also filed as Libtayo®, REGN2810
- Drug: Fianlimab — also filed as REGN3767
- Drug: PLD — also filed as Doxil®, Pegylated liposomal doxorubicin
- Drug: Sarilumab — also filed as Kevzara®, REGN88, SAR153191
- Drug: REGN10597
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessment
measured Up to 3 years
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed